Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 1109-1116

  Xie, Jing ^a   Gabelle, Audrey ^b   Dorey, Aline ^a   Garnier Crussard, Antoine ^a   Perret Liaudet, Armand ^c,f   Delphin Combe, Floriane ^a   Bathsavanis, Anthony ^a   Dauphinot, Virginie ^a   Lehmann, Sylvain ^b   Mercier, Bernadette ^d   Desestret, Virginie ^d,e,f   Roullet Solignac, Isabelle ^d   Vighetto, Alain ^d,e,f   Krolak Salmon, Pierre ^a,e,f  

^a Hopital des Charpennes CHU de Lyon   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

^e UNIVERSITÉ LYON 1   (France)

^f LYON NEUROSCIENCE RESEARCH CENTER   (France)

Author keywords

Alzheimer's disease; cerebrospinal fluid; memory

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; ASSESSMENT OF HUMANS; CEREBROSPINAL FLUID; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FREE AND CUED SELECTIVE RECALL REMINDING TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECALL; VISUAL MEMORY; WORKING MEMORY; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LEARNING; MEMORY DISORDERS; MENTAL HEALTH; NONPARAMETRIC TEST; PHYSIOLOGY; RETROSPECTIVE STUDY;

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MENTAL RECALL; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TAU PROTEINS; VERBAL LEARNING;

EID: 84923696429     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131916     Document Type: Article

References (42)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
3. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology 69, 1859-1867.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
5. KopelmanMD(2002) Disorders of memory. Brain 125, 2152-2190.
6. Janowsky JS, Shimamura AP, Kritchevsky M, Squire LR (1989) Cognitive impairment following frontal lobe damage and its relevance to human amnesia. Behav Neurosci 103, 548-560.
7. Godefroy O, Roussel M, Leclerc X, Leys D (2009) Deficit of episodic memory: Anatomy and related patterns in stroke patients. Eur Neurol 61, 223-229.
8. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
9. Johnson JK, Head E, Kim R, Starr A, Cotman CW (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 56, 1233-1239.
10. Goethals M, Santens P (2001) Posterior cortical atrophy. Two case reports and a review of the literature. Clin Neurol Neurosurg 103, 115-119.
11. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC (2004) Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63, 1168-1174.
12. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study. Lancet Neurol 10, 785-796.
13. Schneider JA, Arvanitakis Z, Leurgans SE, BennettDA(2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66, 200-208.
14. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF (2008) Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms. Ann Neurol 64, 492-498.
15. Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
16. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43, 1683-1689.
17. Grober E, Buschke H (1987) Genuine memory deficits in dementia. Dev Neuropsychol 3, 13-16.
18. Reitan R (1958) Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills 8, 271-276.
19. Wechsler D (1981) The Wechsler Adult Intelligence Scale-Revised, Psychological Corporation, San Antonio.
20. Benton AL (1963) The revised visual retention test: Clinical and experimental applications, Psychological Corporation, New York.
21. Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, Ceccaldi M, PoncetM(2004) Evaluation of visual recognition memory in MCI patients. Neurology 62, 1317-1322.
22. Signoret JL, Benoit N (1991) Examination and memory. Rev Prat 41, 866-868.
23. Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, Thomas-Anterion C, Croisile B, Mollion H, Moreaud O, Salzmann M, Dorey A, Bataillard M, Coste MH, Vighetto A, Krolak-Salmon P (2011) CSF biomarkers in posterior cortical atrophy. Neurology 76, 1782-1788.
24. Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, Peoc'h K, Schraen S, Pasquier F, Touchon J, Hugon J, Lehmann S, Gabelle A (2013) Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement 9, 406-413.
25. Tabaraud F, Leman JP, Milor AM, Roussie JM, Barriere G, Tartary M, Boutros-Toni F, RigaudM(2012) Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand 125, 416-423.
26. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B (1999) Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 156, 531-537.
27. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H,Van Everbroeck B, Cras P, Martin JJ,Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSFbiomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
28. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer N (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
29. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid betaamyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
30. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
31. Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Jack CR, Jr., Josephs KA (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study. Lancet Neurol 11, 868-877.
32. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC (2003) Mild cognitive impairment: Can FDGPET predict who is to rapidly convert to Alzheimer's disease? Neurology 60, 1374-1377.
33. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 63, 2332-2340.
34. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238.
35. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frolich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schroder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78, 379-386.
36. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
37. Schoonenboom NS, Reesink FE,VerweyNA,Kester MI, Teunissen CE, van deVen PM, PijnenburgYA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
38. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613.
39. Davis DG, Schmitt FA,Wekstein DR, MarkesberyWR(1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58, 376-388.
40. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging I (2010) Diagnosisindependent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
41. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R,Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 73, 754-760.
42. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O (2010) Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121-127.